We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

This study has been withdrawn prior to enrollment.
(Lack of accrual)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00993642
First Posted: October 12, 2009
Last Update Posted: March 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Novartis
Board of Regents, State of Louisiana
Information provided by (Responsible Party):
Bridgette Collins-Burow, Tulane University
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: December 2010
  Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)